Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Syrosingopine sensitizes cancer cells to killing by metformin
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
3773162
Author(s)
Benjamin, D.; Colombi, M.; Hindupur, S. K.; Betz, C.; Lane, H. A.; El-Shemerly, M. Y. M.; Lu, M.; Quagliata, L.; Terracciano, L.; Moes, S.; Sharpe, T.; Wodnar-Filipowicz, A.; Moroni, C.; Hall, M. N.
Syrosingopine sensitizes cancer cells to killing by metformin
Journal
Science Advances
Volume
2
Number
12
Pages / Article-Number
e1601756
Abstract
We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated to syrosingopine's known role as an inhibitor of the vesicular monoamine transporters. Syrosingopine binds to the glycolytic enzyme α-enolase in vitro, and the expression of the γ-enolase isoform correlates with nonresponsiveness to the drug combination. Syrosingopine sensitized cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound. Thus, combining syrosingopine and codrugs is a promising therapeutic strategy for clinical application for the treatment of cancer.
Publisher
American Association for the Advancement of Science